COVID-19-induced pneumonia. COVID-19
Conditions
Interventions
Intervention 1: Intervention group: This group includes inpatient cases with mild to moderate respiratory problems that are confirmed for corona infection. In phase II non-randomized clinical trial, a
Sponsors
Esfahan University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: Age more than 18 years Clinical and paraclinical signs and symptoms for COVID19-induced pneumonia inpatient setting Positive PCR for COVID19 Informed consent
Exclusion criteria
Exclusion criteria: Pregnancy A recent medical history of using ACEI and ARB drugs, fludrocortisone, spironolactone, eplerenone, TCA antidepressant, Simvastatin, MAO inhibitors, serotonin inhibitors such as sertraline and citalopram, Triptamins, Alcoholism Heart Failure (EF 5 times of the upper limit normal) Severe renal dysfunction (GFR less than 30cc per min) Any drug side-effects including: Patients’ intolerance, Diarrhea, Gastrointestinal problems Active peptic ulcer Active Bleeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Fever. Timepoint: BID. Method of measurement: Thermometer.;Hemodynamic signs. Timepoint: BID. Method of measurement: P/E.;O2 sat. Timepoint: BID. Method of measurement: Puls-Oximetery.;Clinical symptomes. Timepoint: TDS. Method of measurement: P/E and medical hx. | — |
Secondary
| Measure | Time frame |
|---|---|
| Drug side-effects. Timepoint: Continuous. Method of measurement: PE and MH.;Survival and clinical symptoms. Timepoint: Continuous. Method of measurement: PE and MH. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Hossein Khanahmad
Esfahan University of Medical Sciences
Outcome results
None listed